Cite
HARVARD Citation
Hurvitz, S. et al. (n.d.). P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. Breast. pp. S116-. [Online].